How much revenue did AbbVie generate this year?
AbbVie has achieved a revenue of 56.31 B USD this year.
AbbVie Revenue 2024
AbbVie Revenue
56.31 B USD
Ticker
ABBV
ISIN
US00287Y1091
WKN
A1J84E
In 2024, AbbVie's sales reached 56.31 B USD, a 3.67% difference from the 54.32 B USD sales recorded in the previous year.
The AbbVie Revenue history
| YEAR | REVENUE (undefined USD) | GROSS MARGIN (%) |
|---|---|---|
| 2029e | 74.63 | 48,36 |
| 2028e | 71.83 | 50,25 |
| 2027e | 67.6 | 53,39 |
| 2026e | 63.93 | 56,45 |
| 2025e | 59.51 | 60,65 |
| 2024e | 56.31 | 64,10 |
| 2023 | 54.32 | 66,45 |
| 2022 | 58.05 | 71,53 |
| 2021 | 56.2 | 69,19 |
| 2020 | 45.8 | 66,69 |
| 2019 | 33.27 | 77,14 |
| 2018 | 32.75 | 76,93 |
| 2017 | 28.22 | 74,63 |
| 2016 | 25.64 | 77,32 |
| 2015 | 22.86 | 80,31 |
| 2014 | 19.96 | 77,83 |
| 2013 | 18.79 | 75,62 |
| 2012 | 18.38 | 75,47 |
| 2011 | 17.44 | 73,64 |
| 2010 | 15.64 | 72,59 |
| 2009 | 14.21 | 71,46 |
AbbVie Revenue, EBIT, Net Income US00287Y1091 · A1J84E
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into AbbVie, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by AbbVie from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects AbbVie’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of AbbVie. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into AbbVie’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing AbbVie’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on AbbVie’s growth potential.
AbbVie Revenue, EBIT and net profit per share
| Date | AbbVie Revenue | AbbVie EBIT | AbbVie Net Income |
|---|---|---|---|
| 2029e | 74.63 B undefined | 0 undefined | 31.26 B undefined |
| 2028e | 71.83 B undefined | 36.61 B undefined | 28.8 B undefined |
| 2027e | 67.6 B undefined | 33.83 B undefined | 26.39 B undefined |
| 2026e | 63.93 B undefined | 31.09 B undefined | 24.37 B undefined |
| 2025e | 59.51 B undefined | 28.17 B undefined | 21.72 B undefined |
| 2024e | 56.31 B undefined | 25.74 B undefined | 20.25 B undefined |
| 2023 | 54.32 B undefined | 16.55 B undefined | 4.82 B undefined |
| 2022 | 58.05 B undefined | 20.12 B undefined | 11.78 B undefined |
| 2021 | 56.2 B undefined | 19.47 B undefined | 11.47 B undefined |
| 2020 | 45.8 B undefined | 13.07 B undefined | 4.56 B undefined |
| 2019 | 33.27 B undefined | 13.32 B undefined | 7.84 B undefined |
| 2018 | 32.75 B undefined | 12.07 B undefined | 5.66 B undefined |
| 2017 | 28.22 B undefined | 9.8 B undefined | 5.28 B undefined |
| 2016 | 25.64 B undefined | 9.6 B undefined | 5.92 B undefined |
| 2015 | 22.86 B undefined | 7.87 B undefined | 5.14 B undefined |
| 2014 | 19.96 B undefined | 3.76 B undefined | 1.77 B undefined |
| 2013 | 18.79 B undefined | 6.02 B undefined | 4.13 B undefined |
| 2012 | 18.38 B undefined | 6.3 B undefined | 5.28 B undefined |
| 2011 | 17.44 B undefined | 4.5 B undefined | 3.43 B undefined |
| 2010 | 15.64 B undefined | 5.18 B undefined | 4.18 B undefined |
| 2009 | 14.21 B undefined | 5.13 B undefined | 4.64 B undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2009 | 14.21 B USD | 5.13 B USD | 4.64 B USD |
| 2010 | 15.64 B USD | 5.18 B USD | 4.18 B USD |
| 2011 | 17.44 B USD | 4.5 B USD | 3.43 B USD |
| 2012 | 18.38 B USD | 6.3 B USD | 5.28 B USD |
| 2013 | 18.79 B USD | 6.02 B USD | 4.13 B USD |
| 2014 | 19.96 B USD | 3.76 B USD | 1.77 B USD |
| 2015 | 22.86 B USD | 7.87 B USD | 5.14 B USD |
| 2016 | 25.64 B USD | 9.6 B USD | 5.92 B USD |
| 2017 | 28.22 B USD | 9.8 B USD | 5.28 B USD |
| 2018 | 32.75 B USD | 12.07 B USD | 5.66 B USD |
| 2019 | 33.27 B USD | 13.32 B USD | 7.84 B USD |
| 2020 | 45.8 B USD | 13.07 B USD | 4.56 B USD |
| 2021 | 56.2 B USD | 19.47 B USD | 11.47 B USD |
| 2022 | 58.05 B USD | 20.12 B USD | 11.78 B USD |
| 2023 | 54.32 B USD | 16.55 B USD | 4.82 B USD |
| 2024e | 56.31 B USD | 25.74 B USD | 20.25 B USD |
| 2025e | 59.51 B USD | 28.17 B USD | 21.72 B USD |
| 2026e | 63.93 B USD | 31.09 B USD | 24.37 B USD |
| 2027e | 67.6 B USD | 33.83 B USD | 26.39 B USD |
| 2028e | 71.83 B USD | 36.61 B USD | 28.8 B USD |
| 2029e | 74.63 B USD | 0 USD | 31.26 B USD |
AbbVie stock margins US00287Y1091 · A1J84E
The AbbVie margin analysis displays the gross margin, EBIT margin, as well as the profit margin of AbbVie. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for AbbVie.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the AbbVie's sales revenue. A higher gross margin percentage indicates that the AbbVie retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the AbbVie's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the AbbVie's total revenue generated. When comparing the revenue margin year over year, investors can gauge the AbbVie's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the AbbVie. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the AbbVie's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
AbbVie Margin History
| AbbVie Gross margin | AbbVie Profit margin | AbbVie EBIT margin | AbbVie Profit margin |
|---|---|---|---|
| 2029e | 66.45 % | 0 % | 41.88 % |
| 2028e | 66.45 % | 50.98 % | 40.1 % |
| 2027e | 66.45 % | 50.05 % | 39.04 % |
| 2026e | 66.45 % | 48.63 % | 38.12 % |
| 2025e | 66.45 % | 47.34 % | 36.5 % |
| 2024e | 66.45 % | 45.71 % | 35.97 % |
| 2023 | 66.45 % | 30.47 % | 8.87 % |
| 2022 | 71.53 % | 34.66 % | 20.29 % |
| 2021 | 69.19 % | 34.65 % | 20.41 % |
| 2020 | 66.69 % | 28.53 % | 9.95 % |
| 2019 | 77.14 % | 40.04 % | 23.57 % |
| 2018 | 76.93 % | 36.85 % | 17.27 % |
| 2017 | 74.63 % | 34.74 % | 18.72 % |
| 2016 | 77.32 % | 37.46 % | 23.1 % |
| 2015 | 80.31 % | 34.43 % | 22.5 % |
| 2014 | 77.83 % | 18.85 % | 8.89 % |
| 2013 | 75.62 % | 32.02 % | 21.97 % |
| 2012 | 75.47 % | 34.28 % | 28.7 % |
| 2011 | 73.64 % | 25.79 % | 19.68 % |
| 2010 | 72.59 % | 33.11 % | 26.72 % |
| 2009 | 71.46 % | 36.08 % | 32.62 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2009 | 71.46 % | 36.08 % | 32.62 % |
| 2010 | 72.59 % | 33.11 % | 26.72 % |
| 2011 | 73.64 % | 25.79 % | 19.68 % |
| 2012 | 75.47 % | 34.28 % | 28.7 % |
| 2013 | 75.62 % | 32.02 % | 21.97 % |
| 2014 | 77.83 % | 18.85 % | 8.89 % |
| 2015 | 80.31 % | 34.43 % | 22.5 % |
| 2016 | 77.32 % | 37.46 % | 23.1 % |
| 2017 | 74.63 % | 34.74 % | 18.72 % |
| 2018 | 76.93 % | 36.85 % | 17.27 % |
| 2019 | 77.14 % | 40.04 % | 23.57 % |
| 2020 | 66.69 % | 28.53 % | 9.95 % |
| 2021 | 69.19 % | 34.65 % | 20.41 % |
| 2022 | 71.53 % | 34.66 % | 20.29 % |
| 2023 | 66.45 % | 30.47 % | 8.87 % |
| 2024e | 66.45 % | 45.71 % | 35.97 % |
| 2025e | 66.45 % | 47.34 % | 36.5 % |
| 2026e | 66.45 % | 48.63 % | 38.12 % |
| 2027e | 66.45 % | 50.05 % | 39.04 % |
| 2028e | 66.45 % | 50.98 % | 40.1 % |
| 2029e | 66.45 % | 0 % | 41.88 % |
AbbVie Aktienanalyse
What does AbbVie do?
Abbvie Inc. is a global, research-oriented company specializing in the field of biotechnology and pharmaceuticals. It was founded in 2013 as a spin-off from Abbott Laboratories. Abbvie's headquarters are in North Chicago, Illinois, and it employs over 47,000 people in more than 75 countries worldwide. The company focuses on researching, developing, and marketing high-quality therapies for the treatment of serious and life-threatening diseases. Abbvie has several business divisions, including immunology, oncology, neurology, and virology, and is known for its investments in research and development. Its key products include adalimumab (sold under the brand name Humira) for autoimmune diseases and Imbruvica for chronic lymphocytic leukemia. Abbvie is recognized as a leading company in the biotechnology and pharmaceutical industry due to its focus on innovative therapies and medicines. AbbVie ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding AbbVie's Sales Figures
The sales figures of AbbVie originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing AbbVie’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize AbbVie's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in AbbVie’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about AbbVie stock
How much was the turnover of the company AbbVie compared to the previous year?
The revenue of AbbVie has increased by 3.67% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of AbbVie?
The revenue of AbbVie is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of AbbVie measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of AbbVie so important for investors?
The revenue of AbbVie is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does AbbVie pay?
Over the past 12 months, AbbVie paid a dividend of 5.92 USD . This corresponds to a dividend yield of about 3.36 %. For the coming 12 months, AbbVie is expected to pay a dividend of 6.04 USD.
What is the dividend yield of AbbVie?
The current dividend yield of AbbVie is 3.36 %.
When does AbbVie pay dividends?
AbbVie pays a quarterly dividend. This is distributed in the months of November, February, May, August.
How secure is the dividend of AbbVie?
AbbVie paid dividends every year for the past 101 years.
What is the dividend of AbbVie?
For the upcoming 12 months, dividends amounting to 6.04 USD are expected. This corresponds to a dividend yield of 3.43 %.
In which sector is AbbVie located?
AbbVie is assigned to the 'Health' sector.
Wann musste ich die Aktien von AbbVie kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of AbbVie from 8/15/2024 amounting to 1.55 USD, you needed to have the stock in your portfolio before the ex-date on 7/15/2024.
When did AbbVie pay the last dividend?
The last dividend was paid out on 8/15/2024.
What was the dividend of AbbVie in the year 2023?
In the year 2023, AbbVie distributed 5.64 USD as dividends.
In which currency does AbbVie pay out the dividend?
The dividends of AbbVie are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The AbbVie stock can be added to a savings plan with the following providers: Trade Republic, Scalable Capital and Consorsbank
Andere Kennzahlen von AbbVie
Our stock analysis for AbbVie Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AbbVie Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
